France   LEEM – Les Entreprises du Médicament (Drug Companies)   Key people: Philippe Tcheng, President Philippe Lamoureux, Director LEEM is the French industry association which represents drug companies operating in France and is the most powerful professional organization of drug companies operating in the country. They represent more than 260 member companies,…

France ANSM – Agence Nationale de Sécurité des Médicaments et des Produits de Santé (National Agency for the Safety of Drugs and Health Products)   Key People: Dominique Martin, CEO The National Agency for the Safety of Medicines and Health Products (ANSM) was created by the government in 2011 for strengthening the safety of…

France INCa – Institut National du Cancer (The National Cancer Institute)       The National Cancer Institute (INCa) is the state agency of health and scientific expertise in oncology in charge of coordinating actions to fight against cancer. Created by the public health law of August 9, 2004, it is placed…

France DSS Direction de la Sécurité (Department of Social Security)   Key People: Director General Mathilde Lignot-Leloup The Directorate of Social Security (DSS) supervises all social security organizations: general scheme funds, basic scheme funds of independent professions other than agricultural, or special schemes funds. It also participates in the supervision of complementary…

France Commission des Affaires Sociales de l’Assemblée Nationale (Commission of Social Affairs, National Assembly)   Key People: Brigitte Bourguignon, Chairwoman Olivier Véran, General Reporter The Social Affairs Committee of the National Assembly is one of the eight standing committees of the French National Assembly. The areas of competence of the Social Affairs Committee are…

France PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in French pharma’s industry, regulatory affairs, reimbursement and pricing.   Maurice-Pierre Planel — President of CEPS Maurice-Pierre Planel Has been heading the Economic Committee of Health Products (CEPS) since December 2015.   CEPS contributes to the development of pharmaceutical policy, implements…

France Cancer is the leading cause of death in France, accounting for 28.5% of all deaths in 2014, followed by cardiovascular diseases, which accounted for 25%. However, there are gender differences: 33% of all deaths among men were related to cancer, while this proportion was lower among women (24%). Cardiovascular diseases…

France Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses due to competition to its diabetes and cardiovascular franchises. The growth is largely down to Dupixent — a drug for use…

France As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In France, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) – the country’s drug regulator –…

innovation France is attempting to reposition itself as a globally competitive hub for artificial intelligence R&D, with significant state investment aiming to turn Paris into the next Palo Alto. With rapid digitalization and the ever-increasing invasion of artificial intelligence (AI) into all aspects of modern life, France has found itself left…

France Shedding light on the unique business model of French pharma’s most successful mid-cap.   Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for…

France Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this field, with a number of companies, institutes and hospitals pioneering new forms of treatment and adapting policy to fit the…